T1-3N3b期下咽癌治疗方案的临床结局与预测因素评估:先行颈部淋巴结清扫对比同步放化疗
本回顾性研究纳入48例T1-3N3b期下咽癌患者,先行颈部淋巴结清扫后同步放化疗组18例,单纯同步放化疗组30例。两组在颈部控制率(p=0.000121)和无病生存期(p=0.0256)上差异显著。先行颈部淋巴结清扫后同步放化疗可能改善颈部控制率和无病生存期,在淋巴结可切除的前提下可考虑作为治疗选择。
要点
- 先行颈部淋巴结清扫后同步放化疗组与单纯同步放化疗组的颈部控制率差异显著(p=0.000121)。
- 先行颈部淋巴结清扫后同步放化疗组与单纯同步放化疗组的无病生存期差异显著(p=0.0256)。
- 淋巴结状态是总生存期的显著预后因素。
核心结论
- 在T1-3N3b期下咽癌患者中,先行颈部淋巴结清扫后同步放化疗相比单纯同步放化疗可能改善颈部控制率和无病生存期。
- 在淋巴结可切除的前提下,可考虑将先行颈部淋巴结清扫作为治疗选择。
研究设计与样本
- 回顾性研究,纳入48例T1-3N3b期下咽癌患者,先行颈部淋巴结清扫后同步放化疗组18例,单纯同步放化疗组30例。
- 比较局部控制率、颈部控制率、无转移率、无病生存期、疾病特异性生存期和总生存期。
- 采用Cox比例风险模型进行单因素和多因素分析以识别生存相关临床因素,并分析淋巴结状态和挽救性手术。
主要发现
- 先行颈部淋巴结清扫后同步放化疗组与单纯同步放化疗组在颈部控制率(p=0.000121)和无病生存期(p=0.0256)上差异显著。
- 单因素和多因素分析显示淋巴结状态是总生存期的显著预后因素。
- 先行颈部淋巴结清扫组、同步放化疗-可切除淋巴结组和同步放化疗-不可切除淋巴结组三组间在颈部控制率(p=0.0005)、无病生存期(p=0.0123)、疾病特异性生存期(p=0.0312)和总生存期(p=0.0159)上差异显著,先行颈部淋巴结清扫组结局优于同步放化疗-可切除淋巴结组和同步放化疗-不可切除淋巴结组。
- 考虑挽救性手术的分析中,先行颈部淋巴结清扫组与同步放化疗±挽救性颈部淋巴结清扫组的颈部控制率差异显著(p=0.003)。
临床怎么用
- 作者认为,在淋巴结可切除的前提下,可考虑将先行颈部淋巴结清扫后同步放化疗作为T1-3N3b期下咽癌的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study assessed the efficacy of upfront neck dissection (ND) versus concurrent chemoradiotherapy (CRT) in patients diagnosed with T1-3N3b hypopharyngeal carcinoma (HPC). METHODS: This retrospective study enrolled patients with T1-3N3b HPC who had undergone upfront ND followed by CRT (upfront group) or CRT (CRT group). Local control rate, neck control rate (NCR), metastasis-free rate, disease-free survival (DFS), disease-specific survival, and overall survival (OS) were compared between the upfront and CRT groups. Univariate and multivariate analyses using Cox proportional hazards models were performed to identify the survival-related clinical factors. Lymph node status and salvage surgery were also analyzed. RESULTS: Forty-eight patients were enrolled in this study, with 18 in the upfront group and 30 in the CRT group. The groups differed significantly in terms of NCR (p = 0.000121) and DFS (p = 0.0256). The lymph node status was found to be a significant prognostic factor for OS in univariate and multivariate analyses. When comparing the upfront, CRT-R (resectable lymph nodes), and CRT-UR (unresectable lymph nodes) groups, significant differences were observed in NCR (p = 0.0005), DFS (p = 0.0123), DSS (p = 0.0312), and OS (p = 0.0159). The upfront group had better outcomes compared to both CRT-R and CRT-UR. In the analysis considering salvage surgery, a significant difference was found in the NCR between the upfront and CRT ± salvage ND groups (p = 0.003). CONCLUSION: Upfront ND followed by CRT may improve NCR and DFS in patients with stage T1-3N3b HPC compared to CRT. Upfront ND should be considered as a treatment option, provided resectability is feasible.
引用
- Yamauchi M, Sakai A, Ebisumoto K, et al. Evaluating Clinical Outcomes and Predictive Factors of Treatment Approaches in T1-3N3b Hypopharyngeal Carcinoma: Upfront Neck Dissection Versus Concurrent Chemoradiotherapy. Head Neck. 2025. PMID: 40718935. doi:10.1002/hed.28261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。